Pre-made Begelomab benchmark antibody ( Whole mAb, anti-DPP4/DPP-4 therapeutic antibody, Anti-ADABP/ADCP2/CD26/DPPIV/TP103 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD.
| Products Name (INN Index) | Pre-Made Begelomab biosimilar, Whole mAb, Anti-DPP4/DPP-4 Antibody: Anti-ADABP/ADCP2/CD26/DPPIV/TP103 therapeutic antibody |
|---|---|
| INN Name | Begelomab |
| Target | DPP4 |
| Format | Whole mAb |
| Derivation | Mouse |
| Species Reactivity | Human |
| CH1 Isotype | IgG2b |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II/III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | ADIENNE |
| Conditions Approved | NA |
| Conditions Active | Graft-versus-host disease |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | DPP4/DPP-4 |
| Package |
